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Abstract
Background Curcumin, a pleiotropic substance used for
centuries in traditional medicine, exhibits antioxidant, anti-
inflammatory and antiproliferative efficacy against various
tumours, but the role of curcumin in gastroprotection is
little studied. We determined the effect of curcumin against
gastric haemorrhagic lesions induced by 75% ethanol and
alterations in gastric blood flow (GBF) in rats with
cyclooxygenase-1 (COX-1) and COX-2 activity inhibited
by indomethacin, SC-560 or rofecoxib, inhibited NO-syn-
thase activity, capsaicin denervation and blockade of
TRPV1 receptors by capsazepine.
Methods One hour after ethanol administration, the gastric
mucosal lesions were assessed by planimetry, the GBF was
examined by H2 gas clearance, plasma gastrin was deter-
mined by radioimmunoassay, and the gastric mucosal
mRNA expression of Cdx-2, HIF-1a, HO-1 and SOD 2 was
analysed by RT-PCR.
Results Curcumin, in a dose-dependent manner, reduced
ethanol-induced gastric lesions and significantly increased
GBF and plasma gastrin levels. Curcumin-induced pro-
tection was completely reversed by indomethacin and SC-
560, and significantly attenuated by rofecoxib, L-NNA,
capsaicin denervation and capsazepine. Curcumin down-
regulated Cdx-2 and Hif-1a mRNA expression and
upregulated HO-1 and SOD 2, and these effects were
reversed by L-NNA and further restored by co-treatment of
L-NNA with L-arginine.
Conclusions Curcumin-induced protection against ethanol
damage involves endogenous PG, NO, gastrin and CGRP
released from sensory nerves due to activation of the
vanilloid TRPV1 receptor. This protective effect can be
attributed to the inhibition of HIF-1a and Cdx-2 expression
and the activation of HO-1 and SOD 2 expression.
Keywords Curcumin  Gastric blood flow  Prostaglandin 
Nitric oxide  Afferent sensory fibres  Calcitonin gene
related peptide  Transient potential vanilloid receptor 
Gastrin
Introduction
Curcumin is a hydrophobic polyphenol that imparts the
yellow colour to the spice obtained from the Curcuma longa
root [1, 2]. The first descriptions of the use of curcumin in
traditional Chinese medicine date back to the Tang Dynasty
around 700R AD [3]. In ancient medicine, curcumin was
also used to treat gastrointestinal (GI) diseases such as
indigestion, flatulence, diarrhoea, and even gastric and
duodenal ulcers [4]. Recent studies have proposed anti-
carcinogenic activity of curcumin, as this compound has
been proven to exert a therapeutic effect on several human
cancers including oesophageal, gastric, and small and large
intestinal cancers [5–7]. Curcumin has also shown thera-
peutic potential in the treatment of liver diseases, irrita-
ble bowel syndrome (IBS), Crohn’s disease, colitis, and
bacterial and parasitic infections of the GI tract [5–8].
Curcumin is an effective scavenger of reactive oxygen
and nitrogen metabolites, and exhibits antioxidant and anti-
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inflammatory activity in the upper and lower GI tract
comparable to that exhibited by non-steroidal anti-inflam-
matory drugs (NSAIDs) [7, 9–11]. Curcumin was found to
reduce the expression of mRNA and protein of pro-in-
flammatory COX-2, iNOS and 5-lipoxygenase (5-LOX)
enzymes and suppressed the expression of various proin-
flammatory cytokines including TNF-a, IL-1, IL-6, IL-8
and interferon gamma (INF-c), all essential in the mecha-
nism of inflammation and carcinogenesis [12–14].
Despite the proven multi-target, anti-inflammatory
properties of curcumin, to date only a few experimental
studies have investigated the protective efficacy of curcumin
in the stomach against the formation of acute experimental
gastric mucosal lesions [15, 16]. As a consequence, little is
known about the mediating factors and mechanisms of the
potential protective effects of curcumin in the stomach after
injury by necrotizing agents such as ethanol.
Therefore, we investigated the mechanisms underlying
the gastroprotective effects of curcumin against acute
gastric mucosal lesions induced by ethanol, which is
known as a strong mucosal damaging agent that causes
mucosal injury through its direct contact with the gastric
mucosa. In particular, we attempted to determine the role
played by the gastric blood flow (GBF), and major gas-
troprotective factors such as endogenous prostaglandins
(PG) and nitric oxide (NO) known to cooperate in the
mechanism of gastric mucosal integrity [17, 18], in the
mechanism of curcumin-induced gastric protection against
ethanol injury using the selective and non-selective COX-1
and COX-2 inhibitors and NO-synthase inhibitor, L-NNA.
Previous studies have documented that the capsaicin-sen-
sitive afferent fibres releasing vasodilatory neuropeptides,
such as calcitonin gene-related peptide (CGRP), play a
central role in gastroprotection [19, 20]. The binding sites
for capsaicin, a selective stimulator of these afferent fibres,
have been identified and are referred to as TRPV1 [21].
Importantly, TRPV1 is expressed in afferent nerves, and its
activation results in the release of vasodilatory neuropep-
tides, including CGRP [22]. Interestingly, curcumin has the
same vanilloid ring pharmacophore as capsaicin, and this
vanillyl structure is considered important for curcumin’s
affinity for and activation of TRPV1 [23, 24]. We have
endeavoured to identify the potential contribution of sen-
sory neuropeptides released from sensory afferent nerves
such as CGRP and the involvement of TRPV1, as well as
PG and NO, in the mechanism of the gastroprotective
action of curcumin against ethanol injury. Furthermore, we
determined the gastric mucosal expression of pro-inflam-
matory markers HIF-1a and caudal type homeobox 2 (Cdx-
2), both of which are also recognized as tumour markers
[25, 26], and the expression of antioxidant enzymes HO-1
and SOD 2 [27, 28] in gastric mucosa exposed to ethanol
with or without pretreatment with curcumin.
Materials and methods
The study was conducted in 168 Wistar rats of both sexes,
weighing between 200 and 250 g, which were deprived of
food for 24 h before each experiment and placed in indi-
vidual Bollman-type cages with free access to tap water.
The study was approved by the local ethical committee at
Jagiellonian University Medical College and conducted in
accordance with the Helsinki Declaration.
Experimental design and treatments
In subsequent studies, five major series (A, B, C, D and E)
of experiments (consisting of 6–8 rats each) were carried
out. Series A was used to determine the effect of pre-
treatment with vehicle (saline, i.g.) and curcumin (Sigma-
Aldrich, Schnelldorf, Germany), administered exogenously
in doses ranging from 2.5 mg/kg i.g. to 100 mg/kg i.g.,
against the gastric mucosal lesions induced by 75% etha-
nol. For comparison, pretreatment with a common proton
pump inhibitor, omeprazole (20 mg/kg i.g.; Sigma-Aldrich,
Schnelldorf, Germany), was employed, and rats pretreated
with this proton pump inhibitor received 1 ml of 75%
ethanol (i.g.) 30 min later. Subsequent series B, C, D and E
were carried out to determine the involvement of PG-COX
and NOS-NO systems and capsaicin-sensitive sensory
innervation and vanilloid receptors, respectively, in cur-
cumin-induced gastric protection against ethanol-provoked
mucosal injury.
In series B, designed to examine the contribution of
endogenous PG to the gastroprotective effects of curcumin,
several groups of rats, each consisting of 6–8 animals, were
pretreated 30 min before the i.g application of 75% ethanol
with either (1) vehicle (saline); (2) curcumin (standard dose
of 50 mg/kg i.g.) alone; (3) curcumin (50 mg/kg i.g.)
administered with or without SC-560 (5 mg/kg i.g. Cay-
man Chemical, Ann Arbor, USA.), the selective COX-1
inhibitor [29]; (4) curcumin (50 mg/kg i.g.) administered
with or without rofecoxib (10 mg/kg i.g. Pfizer, Illertissen,
Germany), the highly selective COX-2 inhibitor [29]; or (5)
curcumin (50 mg/kg i.g.) administered without or with
indomethacin (5 mg/kg i.p.), a non-selective COX-1 and
COX-2 inhibitor [30].
In series C, designed to examine the role of NO in cur-
cumin-induced gastroprotection against ethanol damage,
rats were pretreated with L-NNA (20 mg/kg i.p., Sigma-
Aldrich, Schnelldorf, Germany), the non-selective NOS
inhibitor, administered with or without L-arginine (200 mg/
kg i.g., Sigma-Aldrich, Schnelldorf, Germany), a substrate
for NO-synthase [28, 29], combined with vehicle or cur-
cumin (50 mg/kg i.g.) and followed 30 min later by i.g.
application of 1 ml of 75% ethanol.
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Capsaicin-induced functional ablation of sensory
nerves and treatment with capsazepine
In a separate series D group of rats, the irreversible func-
tional ablation of visceral-sensory fibres was performed by
the subcutaneous (s.c.) application of capsaicin adminis-
tered in neurotoxic doses according to the method described
previously by our group [20]. In this set of experiments,
capsaicin (Sigma-Aldrich, Schnelldorf, Germany) was
injected s.c. in incremental doses of 25, 50 and 50 mg/kg,
respectively, over a 3-day period (a total dose of 125 mg/
kg). For each day of capsaicin administration, rats received
a small dose of phenobarbital to counteract respiratory
impairment resulting from daily dosing of this agent. The
effectiveness of denervation was verified by a blink test to
confirm the loss of corneal reflex after administering a drop
of diluted capsaicin directly into the conjunctival sac [20].
Only rats without corneal reflex confirm sensory denerva-
tion, were used to examine the effect of capsaicin dener-
vation on curcumin-induced gastroprotection for at least
2 weeks after administration of the last dose of capsaicin.
In series E rats, the effect of capsazepine (Sigma-
Aldrich, Schnelldorf, Germany), an inhibitor of TRPV-1
receptors [20], on curcumin-induced protection against
ethanol injury was determined. Rats with intact or cap-
saicin-ablated sensory nerve fibres, or those pretreated with
vehicle (saline i.g.) or capsazepine (5 mg/kg i.g.), received
curcumin (50 mg/kg i.g.), with or without CGRP (10 lg/kg
s.c., Sigma-Aldrich, Schnelldorf, Germany), and 30 min
later vehicle-control and capsazepine-treated rats were
exposed to 75% ethanol (1 ml/rat i.g.), administered via
orogastric tube as described above.
Examination of GBF and determination of area
of gastric lesions in rats
with or without pretreatment with curcumin
For the GBF measurement, the animals were anesthetized
with pentobarbital (50 mg/kg i.p.) 1 h after administration
of ethanol. After opening the abdominal cavity, the gastric
blood flow (GBF) was determined using an H2-gas clear-
ance technique as described previously [20, 29, 31]. The
results were expressed as a percentage of the flow recorded
in intact gastric mucosa. The stomach was removed and
dissected along the greater curvature, and macroscopic
evaluation of the area of gastric mucosal lesions was per-
formed with a planimeter (Morphomat, Carl Zeiss, Berlin,
Germany), as described in detail elsewhere [29, 31].
Histological evaluation of gastric lesions
Standardized biopsy specimens from the corpus of the
stomach, incorporating the total length of the gastric wall,
were prepared using 10% buffered formalin for fixation.
The samples were embedded in paraffin, followed by5 lm
sectioning and staining with hematoxylin and eosin for
histology evaluation. A Nikon microscope equipped with a
Microplan II digital image system was used for histological
examination.
Determination of plasma gastrin levels in vehicle-
and curcumin-pretreated rats subjected to 75%
ethanol
Blood samples were taken from selected study groups to
determine the concentration of gastrin by radioimmunoas-
say (RIA) using specific antibodies, as described previ-
ously [28, 29]. Briefly, blood samples were collected from
vena cava of vehicle-control rats and those pretreated with
curcumin, and were placed in tubes containing disodium
acetate. The samples were centrifuged for 15 min
(4000 rpm), and the blood plasma was stored at -20 C
until RIA analysis. The concentration of gastrin in plasma
was determined using anti-gastrin antibodies (rabbit serum
4562, kindly provided by Dr. J. F. Rehfeld, University of
Copenhagen, Denmark), with a final dilution of 1:280000
[29]. The antibodies used in our study recognized gastrin-
17 and gastrin-34 in equal measure. The effectiveness of
gastrin detection, measured as the sensitivity of the
method, amounted to 2.5 pmol/l, while the precision of the
method ranged from 88 to 92%.
Determination of mRNA for HIF-1a, Cdx-2, HO-1
and SOD 2 expression in gastric mucosa by RT-PCR
Biopsy specimens of the gastric mucosa were also taken to
determine the RT-PCR expression of mRNA for Cdx-2,
HIF-1a, HO-1 and SOD 2 in the gastric mucosa collected
from intact rats and those who received 75% ethanol, with
or without the pretreatment with vehicle (saline) or cur-
cumin applied in a gastroprotective dose of 50 mg/kg i.g.
with or without concurrent treatment with L-NNA (20 mg/
kg i.g) alone or combined with L-arginine (200 mg/kg i.g.).
Samples of the gastric mucosa (about 200 mg) were col-
lected in Eppendorf tubes at 0 C using laboratory micro-
scope slides and then immediately immersed in liquid
nitrogen, and stored at -80 C until the RNA isolation
procedure. The RNA was isolated from the gastric mucosa
using the method described by Chomczynski and Sacchi
with Trizol (Invitrogen, Carlsbad, CA, USA) according to
the manufacturer’s protocol [32]. The cDNA was synthe-
sized from total cellular DNA (5 lg) using the Reverse
Transcription System (RTS, Promega, Madison, USA).
The PCR reaction was conducted in an automatic DNA
thermal cycler using 1 lg cDNA and Promega PCR
reagents. To amplify the HIF-1a, Cdx-2, HO-1 and SOD 2
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DNA, specific DNA primers were used (Sigma-Aldrich, St.
Louis, MO, USA) whose sequences, along with annealing
temperature and size of their respective products, are pre-
sented in Table S1. In order to verify the integrity of the
RNA, a control amplification of b-actin was performed
using the same samples (Tab. S1). PCR products were
separated by electrophoresis on a 2% agarose gel con-
taining 0.5 lg/ml of ethidium bromide and then visualized
when exposed to UV light. The location of the expected
PCR products was confirmed by using a control set of PCR
products (O’GeneRuler 50 bp DNA). The densitometry
method (Gel-Pro Analyser, Fotodyne Incorporated, Hart-
land, WI, USA) [29] was employed to compare the
expression of HIF-1a, Cdx-2, HO-1 and SOD 2 with that of
b-actin obtained from the immunoreactive areas of the
gastric mucosa from intact rats as well as in those obtained
from curcumin-pretreated rats exposed to 75% ethanol.
Statistical analysis
Results of the experiment were expressed as mean ± SEM
and the statistical analysis was performed with ANOVA
test and Tukey post hoc test where appropriate. Differences
between estimates of effects were considered significant at
p\ 0.05.
Results
As presented in Fig. 1, intragastric administration of 1 ml
of 75% ethanol in vehicle-pretreated rats resulted in the
formation of necrotic gastric mucosal lesions, and this
effect was accompanied by a significant decrease in the
GBF (p\ 0.05) relative to the respective values of GBF in
intact gastric mucosa. The plasma gastrin level in intact
rats averaged about 22 pM, and the i.g. application of
curcumin at a dose of 2.5 mg/kg had no significant effect
on this plasma gastrin level or the area of gastric lesions
and GBF relative to vehicle-control animals. Pretreatment
with curcumin, applied i.g. in graduated doses of 10, 50
and 100 mg/kg, significantly reduced the area of ethanol-
induced gastric lesions, by about 29, 67 and 89%
(p\ 0.05), respectively, and these effects were accompa-
nied by a significant increase in the GBF and plasma
gastrin levels relative to the respective values in vehicle-
pretreated control rats (p\ 0.05; Fig. 1). Pretreatment with
omeprazole, applied i.g. in a dose of 20 mg/kg, signifi-
cantly reduced the area of gastric lesions and increased the
GBF, similar to that seen with curcumin administered i.g.
in a dose of 100 mg/kg (p\ 0.05).
As shown in Fig. 2, curcumin administered in a dose of
50 mg/kg caused a decrease in the area of ethanol-induced
gastric damage and an increase in GBF similar to those
presented in Fig. 1. The administration of rofecoxib, SC-
560 or indomethacin alone failed to evoke statistically
significant changes in the area of ethanol-induced mucosal
damage and GBF in comparison to the vehicle-control
animals exposed to 75% ethanol (Fig. 2). However, when
curcumin was co-administered with rofecoxib, SC-560 or
indomethacin, a statistically significant increase in the area
of ethanol damage and a significant reduction in GBF were
observed relative to the corresponding values obtained in
rats pretreated with curcumin without concomitant treat-
ment with selective or non-selective COX-1 and COX-2
Fig. 1 Mean area of ethanol-
induced gastric lesions,
alterations in gastric blood flow
(GBF) and plasma gastrin levels
in rats pretreated intragastrically
(i.g.) with vehicle (saline) or
curcumin applied i.g. in
graduated doses from 2.5 mg/kg
to 100 mg/kg and, for
comparison, with the proton
pump inhibitor omeprazole
(20 mg/kg i.g). The results are
mean ± SEM obtained from
seven rats per group. An
asterisk indicates a significant
change (p\ 0.05) relative to the
vehicle-control values
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inhibitors (p\ 0.05; Fig. 2). The concurrent treatment
with 16,16 dimethyl PGE2 (5 lg/kg i.g.) combined with
either the non-selective or selective COX-1 and COX-2
inhibitors restored the decrease in area of these lesions and
the rise in GBF caused by curcumin against ethanol dam-
age (Fig. 2).
Figure 3A1 shows the representative gross appearance
of the gastric mucosa of a rat that was pretreated with
vehicle (saline) and received i.g. 1 ml of 75% ethanol
30 min later. The massive haemorrhagic band-like lesions
are clearly visible (Fig. 3, panel A1). In the gastric mucosa
of rats pretreated with curcumin (50 mg/kg i.g.) and
exposed to 75% ethanol, the area of haemorrhagic lesions
was markedly reduced, reflecting the gastroprotective
effect of this compound (Fig. 3, panel B1). In contrast,
when the NO-synthase inhibitor L-NNA (20 mg/kg i.p.)
was combined with curcumin, the gastroprotective effect of
curcumin was reversed, and the area of gastric lesions was
increased relative to curcumin applied alone (Fig. 3, panel
C1 vs. panel B1). The combined administration of L-argi-
nine (200 mg/kg i.g.) and L-NNA restored the protective
effect of curcumin against ethanol damage as reflected by a
decrease in area of macroscopically assessed gastric lesions
compared with that observed in rats treated with L-NNA
and curcumin but without L-arginine administration (Fig. 3,
panel D1 vs. panel C1).
Figure 3 A2–D2 shows the microscopic appearance of
the gastric mucosa pretreated with vehicle (saline; A2) and
curcumin (50 mg/kg i.g.; B2), both applied i.g. 30 min
before the i.g. instillation of 75% ethanol (1 ml/rat). The
panels C2 and D2 show the effect of L-NNA (20 mg/kg
i.p.) in the presence of curcumin (50 mg/kg i.g.) with or
without L-arginine (200 mg/kg i.g.), respectively. In the
gastric oxyntic mucosa pretreated with vehicle (saline) and
exposed to 75% ethanol (A2), severe destruction of the
surface epithelium and extensive oedema of the submu-
cosal layer infiltrated with leucocytes are observed, along
with haemorrhagic lesions, some of which clearly penetrate
the deeper layers (A2). In addition, there is a distortion of
surface epithelium and a lack of normal glandular archi-
tecture in vehicle-pretreated gastric mucosa exposed to
ethanol (A2). The gastric mucosal haemorrhagic lesions
were markedly reduced and the glandular structure was
partially preserved in gastric mucosa pretreated with cur-
cumin (50 mg/kg i.g.) and exposed 30 min later to ethanol
(B2). In contrast, rats treated with L-NNA (20 mg/kg i.p.)
and administered curcumin (50 mg/kg i.g.; C2), exhibited a
significant loss of glandular architecture, destruction of the
surface epithelium and the appearance of necrotic lesions.
This microscopic observation indicates that the protective
effect of curcumin against ethanol lesions was evidently
lost in curcumin-pretreated animals compromised by
L-NNA. When L-arginine (200 mg/kg i.g.) was combined
with L-NNA, the gastric mucosal haemorrhagic lesions
were reduced in curcumin-treated rats, as reflected by the
partial preservation of surface epithelium and glandular
Fig. 2 The mean area of ethanol-induced gastric lesions and the
alterations in the gastric blood flow (GBF) in rats pretreated
intragastrically (i.g.) with curcumin in a dose of 50 mg/kg with or
without the concurrent treatment with indomethacin (INDO; 5 mg/kg
i.p.), SC-560 (SC; 5 mg/kg i.g.) or rofecoxib (ROFE; 10 mg/kg i.g.)
with or without combination with 16,16 dimethyl PGE2 (5 lg/kg i.g).
Results are mean ± SEM from 6 to 8 rats per group. An asterisk
indicates a statistically significant (p\ 0.05) change relative to the
vehicle control values. The asterisk and cross indicate a statistically
significant change (p\ 0.05) relative to curcumin administered alone.
The cross indicates a significant change (p\ 0.05) relative to each
group treated with COX-1 and COX-2 inhibitor alone
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structure, and the reduction in leukocyte infiltration and
submucosal oedema in the gastric mucosa of these animals
(D2).
Figure 4 presents the quantitative data derived from
experiments with L-NNA (20 mg/kg i.p.) combined with
curcumin (50 mg/kg i.g.), with or without L-arginine
(200 mg/kg i.g.) administration, on the area of ethanol-
induced gastric lesions and the alterations in GBF. The
intraperitoneal administration of L-NNA tended to
increase, though not significantly, the extent of ethanol-
induced gastric mucosal damage and failed to alter the
GBF compared to the corresponding values obtained in the
vehicle-control group with ethanol alone. However, when
L-NNA was combined with curcumin (50 mg/kg i.g.), a
statistically significant increase in the area of the ethanol-
induced damage and a significant reduction in GBF were
observed relative to the corresponding values obtained in
curcumin-pretreated rats without L-NNA administration
(p\ 0.05). Pretreating the gastric mucosa of rats with L-
arginine (200 mg/kg i.g.) alone prior to exposure to 75%
ethanol resulted in a significant reduction in the area of
gastric lesions, along with a significant increase in GBF
(p\ 0.05), thereby reaffirming the gastroprotective activ-
ity of this amino acid (Fig. 4). The intraperitoneal admin-
istration of L-NNA significantly increased the extent of
ethanol-induced gastric mucosa damage and significantly
decreased GBF compared to the corresponding values
obtained in the group with L-arginine alone (p\ 0.05). The
combined administration of L-arginine and L-NNA restored
the curcumin-induced decrease in ethanol-derived lesions
(p\ 0.05) and the accompanying increase in GBF
(p\ 0.05) compared to the corresponding values observed
in the animals treated only with a combination of L-NNA
and curcumin (Fig. 4).
Figure 5 shows that in rats with intact sensory nerves,
pretreatment with curcumin (50 mg/kg i.g.) significantly
reduced the area of ethanol-induced lesions (p\ 0.02) and
significantly increased the GBF (p\ 0.05), similar to the
effects presented in Figs. 1 and 2. When CGRP (10 lg/
kg s.c.) was applied alone before ethanol, the area of gastric
Fig. 3 Representative gross macroscopic and microscopic appear-
ance (using H&E staining) of the gastric mucosa pretreated with
(A) vehicle (saline) or (B) curcumin (50 mg/kg i.g.) 30 min before
per os instillation of 75% ethanol (1 ml/rat) and curcumin-pretreated
gastric mucosa of rats treated with L-NNA (20 mg/kg i.p.) applied
alone (C) or combined with L-arginine (200 mg/kg i.g.) (D) and
exposed to 75% ethanol. The severe gastric haemorrhagic lesions are
clearly visible in the gastric oxyntic mucosa pretreated with vehicle
(saline) and exposed to 75% ethanol (A1). The gastric mucosal
lesions were markedly reduced in gastric mucosa pretreated with
curcumin (50 mg/kg i.g.) and exposed to ethanol (B1). In rats
pretreated with L-NNA (20 mg/kg i.p.) and administered curcumin
(50 mg/kg i.g.), the protective effect of curcumin against ethanol
injury was lost (C1). When L-arginine (200 mg/kg i.g.) was
administered with L-NNA, a curcumin-induced reduction in the
formation of haemorrhagic gastric lesions was observed (D1). In the
vehicle-pretreated rats compromised by ethanol, a severe disruption
of gastric mucosa, accompanied by the loss of glandular architecture
and leucocyte infiltration, is observed (A2). Of note, in curcumin-
pretreated gastric mucosa, relatively mild disruption of gastric
mucosa along with mild oedema and partial preservation of glandular
structure can be observed in comparison with vehicle-control (B2).
The loss of glandular structure and the presence of deep mucosal
lesions were observed in gastric mucosa of rats treated with a
combination of L-NNA and curcumin (C2). In contrast, the mild
disruption of gastric mucosa and a partial restoration of glandular
structure along with mild signs of inflammation were observed in
gastric mucosa of L-arginine-treated rats administered a combination
of L-NNA and curcumin and compromised 30 min later by 75%
ethanol (D2)
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lesions was significantly reduced and the GBF was signifi-
cantly increased (p\ 0.05) relative to animals pretreated
with vehicle (saline) and exposed 30 min later to ethanol
(Fig. 5). The combined administration of CGRP in a dose of
10 lg/kg (s.c.) and curcumin in a standard dose of 50 mg/kg
(i.g.) resulted in a further statistically significant reduction in
the area of ethanol-induced gastric damage (p\ 0.05) and an
accompanying increase in GBF (p\ 0.05) as compared with
animals pretreated with either curcumin or CGRP alone
(Fig. 6). In capsaicin-denervated rats, the i.g. administration
of 75% ethanol significantly increased the mean lesion area
(p\ 0.02) and caused a significant fall in the GBF
(p\ 0.02) relative to ethanol-exposed rats with intact sen-
sory nerves (Fig. 5). The curcumin- or CGRP-induced
decrease in the area of ethanol damage was reversed in
capsaicin-denervated rats, and the GBF was significantly
decreased relative to curcumin- or CGRP-pretreated animals
with intact sensory nerves exposed to ethanol (p\ 0.05;
Fig. 5). When CGRP in a dose of 10 lg/kg (s.c.) was com-
bined with curcumin (50 mg/kg i.g.) in rats with capsaicin
denervation, a significant reduction in the area of ethanol-
induced gastric mucosa damage (p\ 0.05) and a significant
increase in GBF (p\ 0.05) were observed compared with
capsaicin-denervated rats treated with curcumin alone and
exposed 30 min later to ethanol (Fig. 5).
As shown in Fig. 6, the intragastric application of cap-
sazepine alone did not significantly affect the extent of
ethanol-induced damage and had no significant effect on
GBF compared to the corresponding values observed in the
vehicle-pretreated control animals. The administration of
capsazepine combined with curcumin significantly
increased the area of gastric lesions (p\ 0.05) and sig-
nificantly decreased the GBF (p\ 0.05) as compared with
those obtained in curcumin-pretreated rats without cap-
sazepine administration (Fig. 6).
Figure 7 shows the signal expression of mRNA for HIF-
1a, Cdx-2, HO-1 and SOD 2 in the gastric mucosa of intact
rats and those pretreated with curcumin (50 mg/kg i.g.),
with or without L-NNA alone or in combination with L-
arginine. In intact rats, the signal expression of mRNA for
HIF-1a, Cdx-2, HO-1 and SOD 2 was negligible. The i.g.
application of 1 ml of 75% ethanol in the vehicle-control
rats resulted in a statistically significant increase in the
gastric mucosal expression of mRNAs for HIF-1a and
Cdx-2 and significantly decreased the ratio of HO-1 and
SOD 2 mRNA over b-actin mRNA expression compared
with intact gastric mucosa (p\ 0.05; Fig. 7). In curcumin-
pretreated rats, the signal of mucosal expression for all of
these factors was weak (Fig. 7). The administration of
L-NNA significantly increased the expression of mRNA
Fig. 4 The mean area of ethanol lesions and accompanying changes
in the GBF in rats pretreated with curcumin (50 mg/kg i.g.), L-
arginine (200 mg/kg i.g.) alone or in those pretreated with a
combination of L-NNA administered in a dose of 20 mg/kg i.p. and
curcumin (50 mg/kg i.g.) with or without L-arginine (200 mg/kg i.g.).
The results are mean ± SEM recorded in seven rats per group. The
asterisk indicates a significant change (p\ 0.05) relative to the
respective values recorded in the vehicle-control group. The asterisk
and cross indicate a statistically significant change (p\ 0.05)
compared with the values obtained in animals pretreated with L-arg
alone. The cross indicates a statistically significant change (p\ 0.05)
relative to the values obtained in animals pretreated with curcumin.
Double crosses indicate a significant change (p\ 0.05) relative to
animals treated with a combination of L-NNA and curcumin
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for Cdx-2 and HIF-1a and decreased the expression of
mRNA for HO-1 and SOD 2 relative to vehicle-control
gastric mucosa exposed 30 min later to 75% ethanol
(p\ 0.05). A semi-quantitative densitometry examination
confirmed a statistically significant reduction in the ratio of
mRNAs for Cdx-2 and HIF-1a over b-actin mRNA and a
significant increase in the expression of HO-1 and SOD 2
mRNAs in curcumin-pretreated animals relative to the
vehicle-pretreated control group (p\ 0.05). The signal
expression for HIF-1a and Cdx-2 mRNAs was significantly
Fig. 5 The mean area of ethanol-induced gastric lesions and the
changes in gastric blood flow (GBF) in rats with intact sensory nerves
or in those with capsaicin denervation pretreated with CGRP (10 lg/
kg s.c.) or curcumin (50 mg/kg i.g.) applied alone or administered in
combination with CGRP (10 lg/kg s.c.). The results are mean ± -
SEM from 6 to 8 rats per group. The asterisk indicates a significant
change (p\ 0.05) relative to the vehicle-control values. The double
asterisk indicate a significant change (p\ 0.05) relative to the values
obtained in animals pretreated with CGRP alone. The asterisk and
cross indicate a statistically significant change (p\ 0.05) as
compared to treatment with curcumin alone. The cross indicates a
significant change (p\ 0.05) as compared with values obtained in
vehicle-control- or curcumin-treated rats with intact sensory nerves.
The double crosses indicate a significant change (p\ 0.05) compared
with capsaicin-denervated rats treated with curcumin
Fig. 6 The area of ethanol-
induced gastric damage and the
changes in gastric blood flow
(GBF) in rats pretreated with
curcumin (50 mg/kg i.g.), with
or without combination with
capsazepine (5 mg/kg i.g.). The
results are mean ± SEM
recorded in seven rats. The
asterisk indicates a significant
change (p\ 0.05) relative to the
vehicle-control values. The
cross indicates a significant
change (p\ 0.05) relative to
animals pretreated with
curcumin alone
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increased in rats co-administered L-NNA and curcumin
(p\ 0.05; Fig. 7). The semi-quantitative ratio of HIF-1a-
and Cdx-2 mRNA confirmed that the concurrent treatment
with L-NNA and curcumin significantly increased the
expression of HIF-1a- and Cdx-2 mRNA over that recor-
ded in animals treated with curcumin alone (p\ 0.05).
This treatment with L-NNA significantly decreased the
HO-1 and SOD 2 mRNA expression in gastric mucosa of
curcumin-pretreated rats subsequently treated with ethanol
(p\ 0.05). When L-arginine was co-administered with
L-NNA in curcumin-treated rats, the gastric mucosal
expression of HIF-1a and Cdx-2 mRNA was significantly
decreased compared with that detected in rats that were not
administered l-arginine (p\ 0.05; Fig. 7). In contrast, the
concurrent treatment with L-arginine and L-NNA signifi-
cantly increased the expression of HO-1 and SOD 2
mRNAs as compared with that observed in that without L-
arginine administration (p\ 0.05; Fig. 7).
Discussion
The present study was designed to determine the gastro-
protective mechanism of curcumin, a product of curcuma
longa [1–4, 15, 16], against the formation of acute gastric
mucosal lesions induced by ethanol. We confirmed that
ethanol, a topical irritant which acts through direct contact
with the gastric mucosa, caused widespread haemorrhagic
lesions in the rat gastric mucosa. Similar haemorrhagic
ethanol-induced gastric mucosal lesions have been reported
in the human stomach [33]. The preservation of the
integrity of gastric mucosa exposed to a variety of
Fig. 7 Densitometry analysis of mRNA expression for Cdx-2, HIF-
1a, HO-1 and SOD 2 compared to the expression of mRNA for b-
actin in the intact gastric mucosa (line 1), that with vehicle (saline)
and curcumin (50 mg/kg i.g.) pretreatment (lines 2 and 3, respec-
tively), and in those administered L-NNA (20 mg/kg i.p.), with or
without L-arginine (200 mg/kg i.g.) followed by curcumin (50 mg/kg
i.g.) (lines 5 and 6, respectively) and exposed to 75% ethanol. Results
are mean ± SEM of three experiments. The asterisk indicates a
significant change (p\ 0.05) relative to the intact values (graphs 1
and 2) or vehicle-control (graphs 3 and 4). The cross indicates a
significant change (p\ 0.05) relative to animals pretreated with the
vehicle-control (graphs 1 and 2) or with curcumin (50 mg/kg i.g.)
(graphs 3 and 4). The asterisk and cross indicate a significant change
(p\ 0.05) relative to the values obtained in animals pretreated with
curcumin (50 mg/kg i.g.) alone (graphs 1 and 2) or in combination
with L-NNA (20 mg/kg i.p.; graphs 3 and 4). Double crosses indicate
a significant change (p\ 0.05) relative to those obtained in animals
treated with a combination of L-NNA and curcumin (50 mg/kg i.g.)
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damaging agents is dependent on the balance between the
epithelial and subepithelial components regulated by the
proliferative zone of gastric glands and the mucosal
defence mechanisms such as undisturbed mucosal blood
flow, mucus and alkaline secretion and the restitution and
proliferation of mucosal cells [34, 35]. The endogenous
prostaglandins, sulfhydryl compounds, the activation of
endothelial and mucosal generation of NO, hydrogen sul-
fide (H2S) and carbon monoxide (CO) contribute to
mucosal integrity and gastroprotection [36–38].
Here, we demonstrated that curcumin, when given
intragastrically, afforded dose-dependent gastroprotection
against ethanol damage, while increasing GBF and plasma
gastrin levels. A previous study reported that treatment
with Zn(II)-curcumin increased proliferative activity and
enhanced antioxidant mechanisms of gastric mucosa
injured by necrotizing agents [16]. In another work, cur-
cumin reduced oxidative stress and acute gastric mucosal
damage by preventing a reduction in the activity of the
enzymes glutathione dehydrogenase (GSH) and SOD
known to scavenge reactive oxygen metabolites [39]. The
reduced expression of proinflammatory mediators, the
generation of free nitrogen radicals, and the inhibition of
apoptosis and increase in cell proliferation in the gastric
mucosa have been implicated in the mechanism of cur-
cumin-induced gastroprotection against a variety of non-
topical and topical ulcerogenes [40, 41]. Following an
increase in the dose of curcumin, we observed a con-
comitant increase in the GBF and plasma gastrin levels,
suggesting that curcumin protection could involve an
improvement in gastric microcirculation possibly mediated
by gastrin, which is known to exert a trophic effect on
gastric mucosa [42, 43]. Moreover, gastrin has been shown
to intensify cellular metabolism, increase GBF and the
proliferative activity of cells, and enhance the repair pro-
cess and mucosal healing by strengthening the restitution
and regeneration of surface epithelial cells [44]. Gastrin has
been found to exhibit potent gastroprotective and hyper-
emic activity against injury evoked by necrotizing irritants
such as ethanol, in part dependent on endogenous PG and
NO [45]. Therefore, we speculate that the observed
increase in plasma circulating gastrin may help to explain
not only the protective but also the hyperemic activity of
curcumin in the stomach injured by ethanol.
The novelty of our work is that it suggests that cur-
cumin-induced protection may be dependent upon the
reduced mRNA expression of pro-inflammatory mediators
HIF-1a and Cdx-2 in the gastric mucosa. Indeed, the
administration of 75% ethanol in vehicle-control rats
increased the expression of mRNA for HIF-1a and Cdx-2
in the gastric mucosa, but this effect was abrogated by
curcumin. Moreover, curcumin increased the mRNA
expression for anti-inflammatory markers HO-1 and SOD 2
downregulated by ethanol, which seems to explain the
beneficial role of this compound in gastroprotection.
Therefore, we speculate that the activation of antioxidant
enzymes HO-1 and SOD 2 can contribute to curcumin-
induced protection. Our results regarding curcumin-con-
trolled expression of antioxidant and anti-inflammatory
enzyme HO-1 are in accord with a previous report that
curcumin afforded protection against H2O2-mediated
apoptosis via an HO-1-dependent mechanism [46].
The gastroprotective effect of curcumin may result from
its inhibition of prostaglandins derived from COX-2, but
this compound has no direct or indirect inhibitory effect on
COX-1 expression and activity in various systems [47, 48].
PG considered as the major products of COX-1 and COX-2
activity, are regarded as classic mediators of cytoprotection
and when applied exogenously in the non-antisecretory
doses, they are able to prevent the mucosal damage
induced by necrotizing substances (e.g. absolute ethanol)
[47, 48] and contribute to mechanisms of gastroprotection,
gastric adaptation to damaging agents and the healing of
acute and chronic ulcerations [49–51].
In our study, the non-selective (indomethacin) and
selective COX-1 (SC-560) and selective COX-2 (rofe-
coxib) inhibitors, which were used in doses that signifi-
cantly reduced the gastric mucosal generation of PG
[52, 53], were not sufficient in themselves to exacerbate the
ethanol-induced gastric mucosal injury. However, when
indomethacin, rofecoxib and SC-560 were combined with
curcumin, a significant increase was observed in the area of
ethanol damage, accompanied by a decrease in GBF,
compared with animals pretreated with curcumin alone.
Concurrent treatment with a synthetic analogue of PGE2
combined with these COX-1 and COX-2 inhibitors restored
the protective and hyperemic effects of curcumin against
ethanol damage. This indicates that PG synthesized by both
COX isoforms, namely, COX-1 and COX-2 can mediate
the gastroprotective effect of curcumin.
NO acts an important mediator of gastroprotection and
ulcer healing [52, 54]. We observed that the blockade of
NO synthesis in the gastric mucosa following the appli-
cation of L-NNA suppressed the gastroprotective effects of
curcumin, and this effect was accompanied by a marked
reduction in the GBF. Moreover, the application of L-
arginine in a dose which attenuated ethanol-induced gastric
lesions, together with L-NNA, restored the protective and
hyperemic activity of curcumin against ethanol injury. The
L-NNA reversed the curcumin-induced decrease in the
expression of HIF-1a and Cdx-2 mRNAs. In line with this
observation, the concurrent treatment with L-arginine, a
substrate for NO synthase combined with L-NNA attenu-
ated an increase in the expression of HIF-1a and Cdx-2
caused by L-NNA. This indicates that NO could play an
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important role in the protective activity of curcumin due to
its hyperemic and anti-inflammatory properties.
In our present study, exogenous CGRP, the major sen-
sory nerve mediator [44], attenuated gastric lesions and
significantly raised the GBF. In contrast, the capsaicin
denervation augmented the extent of ethanol-damage and
decreased GBF relative to the group of rats with intact
sensory nerves. The capsaicin denervation eliminated the
protective activity of curcumin, and to some extent that of
CGRP applied alone, and reduced the accompanying GBF.
However, when CGRP was combined with curcumin in
capsaicin-denervated rats, a partial restoration of the gas-
troprotective and hyperaemic effects of curcumin was
observed. To the best of our knowledge, this constitutes the
first demonstration that the sensory afferent fibres releasing
neurotransmitters such as CGRP together with NO, possi-
bly derived from cNOS activity, could be involved in the
mechanism of curcumin-induced gastroprotection against
ethanol injury. Taken together, this leads us to speculate
that the mechanism of curcumin-induced protection could
involve an increase in the activity of the afferent sensory
nerves and release of vasoactive CGRP, thus causing
vasodilation and an increase in GBF.
Recent studies have demonstrated the co-localization of
CGRP with the vanilloid receptor (TRPV-1) in the gastric
mucosa of rodents acting as target, along with other neu-
rotransmitters released from sensory fibres [55, 56]. In our
present study, the administration of capsazepine, the
TRPV1 receptor antagonist, which did not further intensify
the ethanol-induced damage of gastric mucosa, substan-
tially attenuated the gastroprotective activity of curcumin.
Thus, based on experiments with capsazepine, we specu-
late that in addition to CGRP and NO, TRPV1 receptors
can participate in the gastroprotective mechanism of cur-
cumin. The possibility that curcumin can act directly
through the activation of the TRPV1 receptors cannot be
excluded, because the vanilloid structure of curcumin has
been implicated in activation of the TRPV1 receptor,
resulting in enhanced apoptosis [57].
In summary, our study demonstrates that curcumin
affords dose-dependent gastroprotective effects against
ethanol damage, accompanied by hyperemia and an
increase in plasma gastrin levels. On one hand, the intra-
gastric administration of curcumin affords protection
against ethanol lesions via an increase in gastric micro-
circulation and the inhibition of expression of proinflam-
matory markers HIF-1a and Cdx-2 in gastric mucosa
exposed to ethanol. On the other hand, curcumin increased
the expression of mRNA for anti-inflammatory factors HO-
1 and SOD 2 in the gastric mucosa injured by ethanol.
Endogenous PG and NO, as well as the activity of cap-
saicin-sensitive visceral sensory fibres releasing CGRP and
the vanilloid receptor (TRPV-1), appear to contribute to the
mechanisms underlying the gastroprotective and hyperemic
effects of curcumin.
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